± MEDIA & ARTS This study employs stylometry to investigate whether the creative writing styles of humans and large language…− MEDIA & ARTS With the rapid application of Generative AI technologies in image generation, style transfer, and creative as…± SCIENCE Using artificial intelligence to identify themes in interview data from a quality improvement program evaluat…+ HEALTH The accurate and rapid identification of bacterial pathogens is essential in clinical setups and medical biod…± HEALTH Introduction Transparency has emerged as a foundational condition for trustworthy Artificial Intelligence (AI…± HEALTH Background Global developmental delay (GDD) frequently precedes intellectual disability (ID), but no validate…− HEALTH Artificial intelligence (AI) tools are entering veterinary diagnostic laboratory service, but reported model…+ HEALTH Antimicrobial biocides play a crucial role in infection control. Although traditional detection methods are a…
TruaceTracing the truth around AITuesday, August 25, 2026
Subscribe
TRV-2026-0806Certified recordPeer-reviewed

Integration of single-cell transcriptomics and genomic mutation analysis identifies an immunotherapy-resistant tumor subcluster and validates ARNTL2 as a malignant driver in lung adenocarcinoma

Immunotherapy resistance in lung adenocarcinoma (LUAD) remains a critical clinical challenge, and the mechanisms underlying resistance-associated intratumoral heterogeneity are poorly characterized. We performed single-cell RNA sequencing of LUAD patients receiving neoadjuvant immunotherapy (responders vs. non-responders), integrating inferCNV, GSVA, and differential expression analyses. Cluster-specific genes were validated across seven independent cohorts (TCGA-LUAD, GSE13213, GSE26939, GSE29016, GSE30219, GSE…

Health · G Space — documented gain · certified 2026-08-17 · v1 · article view · machine-readable

Current reading — gain

A CoxBoost + survivalSVM prognostic model built from resistance-associated cluster genes achieved C-index 0.686 and stratified LUAD patients with HR 2.54-10.51, with low-risk patients showing greater immune infiltration and ARNTL2 knockdown suppressing proliferation and invasion in A549 and H1299 cells.

Evidence

Reader signal

How should this claim be treated?

Cite this record

Truvace Impact Record TRV-2026-0806, v1: “Integration of single-cell transcriptomics and genomic mutation analysis identifies an immunotherapy-resistant tumor subcluster and validates ARNTL2 as a malignant driver in lung adenocarcinoma.” Truvace, 2026-08-17. /record/TRV-2026-0806 (accessed at citation time). sha256 0fa749e756374331…

Calibration history

Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.

  1. Certifiedv10fa749e75637…

    Certified into the record

Verify this record
How to verify without trusting this page

Fetch the canonical text of any version from /api/record/TRV-2026-0806 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.